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1 Drug description 
Generic/Brand name/ATC code:  
Dabrafenib/Tafinlar®/GSK2118436 
Developer/Company:  
GlaxoSmithKline Trading Services Limited 
Description:  
Dabrafenib is a selective adenosine triphosphatase (ATP)-competitive rapid-
ly accelerated fibrosarcoma (RAF) kinase inhibitor and it inhibits, based on 
in-vitro data, all types of BRAF protein kinase activity [1]. Since BRAF is 
involved in stimulating proliferation, this gene, when mutated, may lead to 
uncontrolled tumor cell division and the development of cancer. Dabrafenib 
is exclusively used for the treatment of patients with a melanoma caused by 
a BRAF V600 mutation [2].  
The therapy with dabrafenib requires the supervision by a doctor experi-
enced in cancer treatment. Before the prescription of the drug, patients have 
to undergo a test to confirm tumor BRAF V600 mutation [2]. 
The recommended dose of dabrafenib is 150 mg twice a day. 50 and 75 mg 
capsules are available for oral administration. Therapy should be continued 
until the disease deteriorates or unacceptable adverse effects occur [2]. 
 
2 Indication 
Previously untreated subjects with BRAF mutation-positive advanced 
(stage III) or metastatic (stage IV) melanoma. 
 
3 Current regulatory status 
In August 2013, the European Medicines Agency (EMA) authorized 
dabrafenib as “monotherapy for the treatment of adult patients with unre-
sectable or metastatic melanoma with BRAF V600 mutation”. BRAF V600 
mutation must be detected by a test and the drug should not be used in pa-
tients with wild-type BRAF melanoma [2]. The market authorisation fol-
lowed the recommendation of the Committee for Medicinal Products for 
Human Use (CHMP), which stated a positive benefit-to-risk balance for the 
drug [3].  
In May 2013 the U.S. Food and Drug Administration (FDA) authorized 
dabrafenib “for the treatment of patients with unresectable or metastatic 
melanoma with BRAF V600E mutation as detected by an FDA-approved 
test”. The drug is not indicated for the treatment of wild-type BRAF mela-
noma [4]. 
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4 Burden of disease 
Melanoma is the most severe type of skin cancer with its incidence increas-
ing worldwide. While in 1990 the estimated age-standardized incidence rates 
of melanoma in men and women were 2.3 and 2.2/100,000 people, respec-
tively, in 2008 they were 3.1 and 2.8/100,000 people. According to the Na-
tional Cancer Institute’s SEER Cancer Statistics Review, the age-adjusted 
incidence rate of melanoma in the US was 21.1/100,000 people per year 
(based on cases diagnosed in 2006-2010). Melanoma was diagnosed at a me-
dium age of 61 years. At the same time the age-standardized mortality rate 
was 2.7/100,000 people with a medium age of death of 69 years [5]. The inci-
dence of melanoma is rising in Central Europe as well, having reached a rate 
of 10-15/100,000 people in the year 2000 [6]. About 10-15% of all patients 
with cutaneous melanoma will develop metastases [7].  
About 50% of all melanomas have BRAF mutations and more than 75 so-
matic mutations in the BRAF gene have been identified in melanoma. All of 
these mutations are at V600 with 80-90% of these showing a V600E (i.e. 
V600Glu) and 10-20% a V600K (i.e. V600Lys) mutation [8, 9]. In small sub-
sets of melanoma also other activating mutations like c-KIT mutations or 
platelet-derived growth factor receptor alpha (PDGFRA) mutations have 
been described [10, 11]. 
For the development of melanoma, genetic and environmental risk factors 
can be identified. Ten percent of melanomas are induced by familial factors 
and it is assumed that multiple genes are involved. Further 10-20% of mela-
nomas develop from atypical nevi, ascribing a 3-20 times higher risk to peo-
ple with this feature. Furthermore it is suspected that people with a high 
number of nevi (more than 25) are at greater risk of developing melanoma. 
Other risk factors include the exposure to sunlight and ultraviolet radiation 
(e.g. tanning beds) and phenotypic traits such as light skin [6, 12].  
The seventh edition of the tumor node metastasis (TNM) system classifies 
melanoma into four stages (I-IV). The division is based on the thickness, mi-
totic rate and ulceration of the primary tumor (T), the affection of lymph 
nodes (N) including satellite lesions and in-transit metastases and the pres-
ence of distant metastases (M). Further prognostic factors include age, gen-
der and location whereas younger patients, women and patients with tumors 
affecting the upper extremities have a better prognosis [13]. While stages I 
and II describe local early melanomas, stages III and IV indicate more ad-
vanced cancer [14]. Stage III includes the affection of regional lymph nodes 
or the presence of satellite metastases or in-transit metastases and stage IV is 
characterized by the presence of distant metastases. There are sub-
classifications for all stages [13].  
In 2010, 1,436 people in Austria were diagnosed with melanoma, which cor-
relates with an age-standardized incidence rate of 11.8/100,000 people [15]. 
Of those, about 9% had already disseminated tumors or died from melano-
ma [16], resulting in about 130 persons with advanced melanoma per year. 
Considering the proportion of BRAF mutations in melanoma, the number of 
patients present with BRAF-positive metastatic melanoma each year is 
about 65 patients in Austria. The age-standardized mortality rate was 
2.4/100,000 people, which means that 376 Austrians died of melanoma in 
2010 [17]. Both melanoma incidence and mortality tend to be higher in men 
[15, 17]. 
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5 Current treatment 
Since melanoma that has spread to distant sites (e.g. unresectable stage III 
and stage IV) is rarely curable, the treatment of these melanomas focuses on 
the reduction of symptoms caused by metastases, the prevention of further 
tumor spread and on palliative care [10]. Some approaches may provide 
clinically relevant benefits for appropriately chosen patient groups with 
metastatic melanoma. These include surgical metastasectomy, immunother-
apy, targeted therapy and radiation therapy to symptomatic sites of metasta-
ses [18]. Until recently, cytotoxic chemotherapy was widely used as standard 
treatment of metastatic melanoma. 
b Surgery: Surgical excision is the primary treatment for localized 
melanoma. But also for metastatic melanoma, it is an option to de-
lay the need for systemic treatment, especially in patients with a 
very limited number of metastases. Metastasectomy may also be 
used to eradicate residual disease with patients having shown good 
response to systemic therapy [18]. 
b Chemotherapy: Common agents being used include dacarbazine, 
temozolomide, or fotemustine. Their response rates are typically 
less than 20 percent and they have not been shown to improve over-
all survival in patients with advanced melanoma [10]. Consequently 
the role of chemotherapy is limited to patients who are not candi-
dates for treatment with immunotherapy and those who have pro-
gressed after optimal treatment with other options [18]. 
b Immunotherapy: Immunotherapy is an established method for the 
treatment of metastatic melanoma. It includes treatment with high-
dose interleukin-2 (IL-2) that has shown long-term disease-free 
survival in a small minority of treated patients and may result in 
cure. Because of its severe toxicities (cardiovascular, respiratory, in-
fectious), it remains a treatment option only for patients in good 
condition [18].   
Treatment with ipilimumab, a monoclonal antibody that targets 
CTLA-4, significantly increases median overall survival in both 
previously untreated and previously treated patients with metastat-
ic or unresectable melanoma, but it is also associated with a variety 
of clinically significant autoimmune side effects [18]. 
b Targeted therapy: Approximately one half of melanomas have a 
V600 BRAF mutation that activates the mitogen-activated protein 
kinase (MAPK) pathway. BRAF inhibition produces rapid tumor 
regression in the majority of patients with V600-mutant melanoma, 
including those with an extensive tumor burden and disease-related 
symptoms. For the inhibition of BRAF, vemurafenib or dabrafenib 
are currently used. The downstream inhibition of the mitogen-
activated ERK-[extracellular signal-regulated kinase]activating ki-
nase (MEK) with trametinib may also be a treatment option [18]. 
Furthermore, for patients with melanoma harbouring c-KIT or 
PDGFRA mutations, early data suggest that therapy with imatinib 
or nilotenib may be a treatment option [10, 19, 20]. 
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b Radiation therapy: Radiation therapy may play a palliative role for 
symptomatic localized areas of disease or as a whole-brain radiation 
therapy which can prolong survival, especially if the tumor outside 
the brain is controlled [10, 18]. 
 
6 Evidence 
A systematic literature search was conducted on the 9th of October 2013 in 
medical databases Ovid Medline/Pubmed, EMBASE, the Cochrane Li-
brary and the CRD, and resulted in 288 records. Of those, 9 records report-
ing results of one phase III trial [21-25] and 2 phase I/II trials [26-29] were 
included. 
In addition, a hand search including reference lists of topic-related reviews 
or articles and the websites of the EMA and the FDA was performed, re-
sulting in no additional publications. Among the material that the manu-
facturer had sent on request, one poster publication of an already identi-
fied conference abstract was retrieved [30].  
In summary, 3 full-text publications and 7 conference abstracts or poster 
publications reporting on 1 phase III trial [22-24, 30] and 2 phase I/II tri-
als [11-14] were included. 
 
6.1 Efficacy and safety – phase III studies 
Table 1: Summary of efficacy 
Study title  
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised 
controlled trial (BREAK-3) 
Study  
identifier 
NCT 01227889, EudraCT 2009-015298-11 
Design Randomised controlled, open-label, international, multi-centre trial; crossover 
assignment; 
N = 250 (187 vs. 63); 
allocation randomly (3:1 ratio) to dabrafenib or dacarbazine (DTIC); 
Duration  Enrolment: December 2010 to September 2011 
Median follow-up:  
Dabrafenib: 10.5 months (NR) 
DTIC: 9.9 months (NR) 
Cut-off dates for analyses: June 2012 (and December 2012 for OS) 
Hypothesis Superiority 
Funding GlaxoSmithKline 
Treatment 
groups 
Intervention 
(n=187) 
Dabrafenib 150 mg twice daily PO 
Control 
(n=63) 
Dacarbazine (DTIC) 1000 mg/m², every 3 weeks until initial 
progression;  
Subjects who initially receive DTIC will be allowed to receive 
dabrafenib 150 mg twice daily after initial progression. 
radiation therapy  
1 phase III trial and       
2 phase II trials  
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Endpoints 
and 
definitions 
Progression-free 
survival 
(primary outcome) 
PFS Time from randomisation to the earliest date of 
radiographic or photographic disease progression or 
death due to any cause. PFS was assessed by the 
individual investigator. 
Overall survival 
(secondary 
outcome) 
OS Time from randomisation to death due to any cause. 
Progression-free 
survival 2 
(secondary 
outcome) 
PFS 2 For subjects randomised to the DTIC treatment group 
the time to progression or death after cross-over to 
dabrafenib after initial progression on DTIC. 
Objective response 
rate (secondary 
outcome) 
ORR Percentage of subjects achieving either a complete or 
partial tumour response (CR/PR) according to RECIST 
version 1.1 (assessed by the investigator and a masked 
independent review committee (IRC)). 
Progression-free 
survival (secondary 
outcome) 
PFS - I Progression-free survival as assessed by the IRC. 
Duration of 
response 
(secondary 
outcome) 
DOR Time from first documented evidence of PR or CR until 
the first documented sign of disease progression or 
death due to any cause. 
Quality of life 
(secondary 
outcome) 
QoL Patient self-reported; EORTC-QLQ-C30 and EQ-5D were 
used for evaluation. 
Safety and 
tolerability 
(secondary 
outcome) 
S+T NR 
Results and analysis 
Analysis  
description 
ITT-analysis; 
Primary endpoint: PFS assessed by the individual investigator; sample size: 200 patients 
were needed to observe 102 PFS events with statistical power of 99.7% to detect a HR of 
0.33 (median PFS of 2 months in patients who received DTIC and 6 months in patients 
who received dabrafenib) using a one-sided log-rank test with α=0.02. 
Analysis  
population 
Inclusion b adults at least 18 years of age 
b advanced (unresectable stage III) or metastatic (stage IV) 
melanoma that is BRAF-mutation positive (V600E) 
b treatment-naive for advanced (unresectable) or metastatic 
melanoma, with the exception of Interleukin 2 (IL-2)  
b measurable disease according to RECIST 1.1 criteria 
b Eastern Cooperative Oncology Group (ECOG) performance status 
of 0-1 
Exclusion b cancer therapy (chemotherapy, radiation therapy, immunotherapy, 
biologic therapy or surgery) within 4 weeks 
b previous treatment for metastatic melanoma, including treatment 
with BRAF or MEK inhibitor 
b previous malignancy within the past 5 years  
b history of Human Immunodeficiency Virus infection 
b active central nervous system disease 
b acute coronary syndrome, coronary angioplasty, placement of 
stents or cardiac arrhythmia (other than sinus arrhythmias) within 
the previous 24 weeks 
Characteristics Median age (years): 50 (21-82) vs. 53 (22-93) 
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Female (%): 41 vs. 40 
Ethnicity_Caucasian/Asian/Others (%): 100/0/0 vs. 98/0/2 
ECOG performance status 0/≥1/unknown (%): 70/25/5 vs. 66/33/1 
BRAF V600 mutation subtype_V600E/V600K (%): 98/2 vs. 99/1 
Disease staging_unresectable III+IVM1a+IVb/IVM1c (%): 33/67 vs. 
34/66 
Baseline LDH_elevated/normal/unknown (%): 27/63/10 vs. 35/62/3 
No previous treatment/previous treatment (%): 2/98 vs. 3/97 
Results 
(interim 
analysis 10 
mo f/up) 
Treatment group DTIC Dabrafenib 
Number of subjects N = 63 N = 187 
PFS (months) 
median 
95% CI 
 
2.7 
1.5 - 3.2 
 
6.9 
5.2 - 9.0 
ORR (%) 
median 
95% CI 
 
24 
14.0 - 36.2 
 
59 
51.4 - 66.0 
DOR (months) 
median 
95% CI 
 
7.6 
5.0 - 9.7 
 
8.0 
6.6 - 11.5 
Results 
(interim 
analysis 15 
mo f/up) 
OS (months) 
median 
95% CI  
 
15.6 
12.7 - NR 
 
18.2 
16.6 -NR 
Effect 
estimate per 
comparison(
interim 
analysis 10 
mo f/up) 
Comparison groups  Dabrafenib vs. DTIC 
PFS HR 0.37 
95% CI 0.24 - 0.58 
P value  <0.0001 
ORR Difference in response 
rates 
35% 
95% CI 20.9% - 48.7% 
P value NR 
DR Point estimate NR 
95% CI NR 
P value  NR 
Effect 
estimate per 
comparison(
interim 
analysis 15 
mo f/up) 
OS HR 0.76 
95% CI 0.48 - 1.21 
P value  NR 
Abbreviations: BRAF … B type of rapidly accelerated fibrosarcoma; CI … Confidence interval; DOR … Duration of response; 
DTIC … Dacarbazine; ECOG … Eastern Cooperative Oncology Group; f/up …Follow-up; HR … Hazard ratio; ITT … In-
tent-to-treat; mo…Months; MEK … Mitogen-activated ERK-[extracellular signal-regulated kinase] activating kinase; NR … 
Not reported; ORR … Overall response rate; OS … Overall survival; PFS … Progression-free survival; QoL … Quality of life; 
RECIST … Response Evaluation Criteria in Solid Tumors; S + T… Safety and tolerability 
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Table 2: Most frequent treatment-related adverse events (interim analysis 10 mo f/up) 
BREAK-3 (NCT 01227889) 
Grade (according  
to CTC version 4.0) Outcome [n (%)] Dabrafenib (n=187) DTIC (n=59) 
Serious adverse 
events (SAE) 
Any event 53 (28) 14 (24) 
Squamous cell carcinoma, 
keratoacanthoma 18 (10) 0 
Pyrexia 9 (5) 0 
Basal cell carcinoma 4 (2) 0 
Chills 3 (2) 0 
Atrial fibrillation 3 (2) 0 
Ejection fraction decreased 3 (2) 0 
Malignant melanoma 3 (2) 0 
Myocardial infarction 2 (1) 0 
Vomiting 2 (1) 1 (2) 
Hypotension 2 (1) 0 
All Grades Hyperkeratosis 67 (36) 1 (2) 
Rash 56 (30) 0 
Alopecia 50 (27) 2 (3) 
Skin papilloma 42 (22) 0 
Palmar-plantar hyperkeratosis 36 (19) 1 (2) 
Arthralgia 36 (19) 0 
Fatigue 33 (18) 13 (22) 
Headache 34 (18) 2 (3) 
Pyrexia 30 (16) 0 
Nausea 26 (14) 23 (39) 
Asthenia 27 (14) 7 (12) 
Squamous cell carcinoma, 
keratoacanthoma 
18 (10) 0 
Grade 3 Squamous cell carcinoma, 
keratoacanthoma 
14 (7) 0 
Pyrexia 5 (3) 0 
Palmar-plantar hyperkeratosis 4 (2) 0 
Arthralgia 2 (1) 0 
Fatigue 2 (1) 0 
Hyperkeratosis 2 (1) 0 
Alopecia 1 (<1) 0 
Grade 4 Hyperkeratosis 1 (<1) 0 
Abbreviations: CTC … Common Terminology Criteria; DTIC … dacarbazine; SAE … Serious adverse event 
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The BREAK-3 trial is an ongoing international, multi-centre, open-label 
phase III randomised controlled trial (RCT) with study centres in the Euro-
pean Union, North America and Australia [6-10]. The aim of the study is to 
compare the efficacy, safety, and tolerability of dabrafenib to dacarbazine 
(DTIC), in subjects with BRAF-mutant advanced (stage III) or metastatic 
(stage IV) melanoma and an ECOG performance status of 0 or 1. 250 pa-
tients aged 18 years or older with previously untreated stage IV or unresec-
table stage III BRAF V600E mutation-positive melanoma were included. 187 
patients were randomly assigned to dabrafenib 150 mg orally twice daily, 
and 63 were allocated to DTIC, 1000 mg/m² every 3 weeks until initial pro-
gression. Subjects who progressed on DTIC were allowed to cross over to an 
optional extension arm of the study to receive dabrafenib.  
The included patients were about 50 years of age and by the majority men 
(60%). Nearly all of them were Caucasians [24].  
In an interim analysis in June 2012 after a median follow-up of about 10 
months, 38% of patients treated with dabrafenib and 8% of patients treated 
with DTIC were still on therapy and continue to be followed for progression 
[22]. For the primary endpoint, progression-free survival (PFS), the interim 
analysis showed a statistically significant improvement in favour of the in-
tervention group assessed by the individual investigator (dabrafenib 6.9 
months vs. DTIC 2.9 months; HR 0.37 (95% CI 0.24 - 0.58; p<0.0001). The 
secondary end point, objective response rate (ORR) was higher with 59% in 
the dabrafenib compared with 24% in the DTIC group, but it was not re-
ported whether these were complete responses (CR) or partial responses 
(PR). The estimated median duration of response (DOR) was 8.0 and 7.6 
months, respectively [22]. 
At the time of an updated interim analysis in December 2012 (median fol-
low-up of about 15 months), 78 patients (42%) in the dabrafenib group and 
28 patients (44%) in the DTIC group had died. There was no statistically 
significant difference in overall survival (OS) (dabrafenib 18.2 months vs. 
DTIC 15.6 months; HR 0.76 (95% CI 0.48 - 1.21)), but data are still not ma-
ture and may be confounded by the crossover of patients in the DTIC group 
after disease progression to dabrafenib (at the date of analysis 36 of the 63 
patients in the DTIC group had crossed over) [22]. 
Quality of life (QOL) was measured by the European Organization for Re-
search and Treatment of Cancer Quality of Life Questionnaire Core 30 
(EORTC-QLQ-C30) and the EuroQol 5D (EQ-5D) questionnaires. There 
was no statistically significant or clinically meaningful difference between 
dabrafenib and DTIC in overall global health status scores, the functionality 
scores and cognitive functioning scores at week 6 and week 12, but im-
provements in the emotional functioning scores and in symptom dimensions 
in favour of dabrafenib were reported without information on the statistical 
significance [21].   
Nevertheless, there are no meaningful data on QoL after week 15 of the 
study period, since the number of assessments decreased throughout the tri-
al [31]. 
ongoing international 
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At the time of the interim analysis in June 2012 there was no difference in 
serious adverse events (SAE) between the two treatment groups (dabrafenib 
28% vs. DTIC 24%), with one fatal SAE in the intervention group (myocar-
dial infarction/acute coronary syndrome, possibly related to study treat-
ment) and none in the DTIC group. The most frequent SAEs in the dabraf-
enib group were squamous cell carcinoma/keratoacanthoma (10%) and py-
rexia (5%), while none of these SAEs occurred in the DTIC group (see Table 
2) [22].  
In general, the majority of the adverse events (AEs) were lower-grade, and 
toxic effects of grade 3 - 4 were rather uncommon. In patients receiving 
dabrafenib, the most common AEs were hyperkeratosis, rash, alopecia, and 
skin papillomas, while nausea, vomiting, fatigue, and neutropenia were 
more frequent in the DTIC group. A publication presenting data of an earli-
er interim analysis in December 2011 (5 months follow-up) reported a dose 
reduction of dabrafenib due to an AE in 52 (28%) patients, and 5 (3%) pa-
tients discontinued the drug because of AEs. In the DTIC group, dose re-
duction was needed in 10 (17%) patients and 2 (3%) patients discontinued 
the drug [24]. 
 
6.2 Efficacy and safety – further studies 
A multicentre, single-arm phase II trial (BREAK-2) [26, 29] assessed the 
safety and clinical activity of dabrafenib. 76 patients (83%) with histologi-
cally confirmed stage IV BRAF V600E and 16 patients (17%) with histologi-
cally confirmed stage IV BRAF V600K-mutant melanoma with or without 
(16%) previous systemic therapy received orally 150 mg dabrafenib twice 
daily until disease progression, death, or unacceptable AEs. Confirmed re-
sponse was reported in 59% (95% CI 48.2 - 70.3) of the BRAF V600E group 
and in 13% (95% CI 0 - 28.7) of the BRAF V600K group. Median PFS in the 
BRAF V600E and BRAF V600K groups was 6.3 months and 4.5 months, and 
median OS was 13.1 months and 12.9 months, respectively.   
The most common AEs were arthralgia (33%), hyperkeratosis (27%), and 
pyrexia (24%). SAEs occurred in 27% of the patients and 10% of all patients 
developed squamous cell carcinoma.  
Another multicentre, open-label, phase II trial (BREAK-MB) [27, 28] evalu-
ated the effect of 150 mg dabrafenib twice a day in 172 patients with histo-
logically confirmed V600Glu or V600Lys BRAF-mutant melanoma with 
(cohort A) or without previous local treatment for brain metastases (cohort 
B). 
39.2% (95% CI 28.0 - 51.2) of the patients with V600Glu BRAF-mutant mel-
anoma in cohort A and 30.8%, (95% CI 19.9 - 43.4) in cohort B achieved an 
overall intracranial response. Of the patients with V600Lys BRAF-mutant 
melanoma, 6.7% (95% CI 0.2 - 31.9) in cohort A and 22.2% (95% CI 6.4 - 
47.6) in cohort B achieved an overall intracranial response.  
Treatment-related AEs of grade 3 or worse occurred in 22% of all patients 
and (6%) patients developed squamous-cell carcinoma. The three most fre-
quent AEs were pyrexia (6%), intracranial haemorrhage (6%) and squa-
mous-cell carcinoma (6%).  
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7 Estimated costs 
For Austria, the price of dabrafenib is not known yet. In Germany one pack-
age of dabrafenib containing 120 75 mg tablets will cost € 8,551 [32]. For pa-
tients with BRAF mutation-positive advanced or metastatic melanoma, the 
recommended dose is 150 mg twice daily as a continuous treatment. This re-
sults in costs of about € 285 per day, which equals € 8,550 per month.  
 
8 Ongoing research 
Besides the BREAK-3 trial (NCT 01227889), of which interim results have 
been presented in this report, 3 further on-going phase III trials investigat-
ing dabrafenib were identified by a search in the databases ClinicalTri-
als.gov and cinicaltrialsregister.eu. All trials are conducted in patients with 
BRAF mutation-positive melanoma. 
NCT01584648 (EudraCT 2011-006087-49): A randomised, double-blind 
study for dabrafenib in combination with the MEK inhibitor trametinib to 
dabrafenib alone as first-line therapy in subjects with unresectable (stage 
IIIC) or metastatic (stage IV) BRAFV600E/K mutation-positive cutaneous mel-
anoma. The completion of the study is planned for January 2015. 
NCT01682083 (EudraCT 2012-001266-15): A randomised double-blind 
study of dabrafenib in combination with trametinib versus two placebos in 
the adjuvant treatment of high-risk BRAFV600 mutation-positive melanoma 
after surgical resection. The estimated study completion date is July 2015. 
NCT01597908 (EudraCT 2011-006088-23): A randomised, open-label study 
comparing the combination of dabrafenib and trametinib to the BRAF in-
hibitor vemurafenib in subjects with unresectable (stage IIIC) or metastatic 
(stage IV) BRAFV600E/K mutation-positive cutaneous melanoma. The estimat-
ed study completion date is June 2015. 
In addition, there are 6 ongoing phase I/II trials for dabrafenib alone or in 
combination for patients with BRAF mutation-positive melanoma and 12 
ongoing phase I/II trials investigating dabrafenib in various other types of 
BRAF mutation-positive cancer (e.g. non-small cell lung cancer, thyroid 
cancer, colorectal cancer). 
 
9 Commentary 
Metastatic melanoma has a poor prognosis with a median survival for pa-
tients with stage IV melanoma ranging from 6 to 9 months and a 3-year sur-
vival rate of only 10-15% [33, 34]. Generally, metastatic melanoma is diffi-
cult to treat because advanced melanomas are refractory to most standard 
systemic therapies and therapeutic options are limited [10]. Even though 
dacarbazine was considered as standard therapy for the treatment of system-
ic metastatic disease, response rates are low (7-12% of patients) [34]. Accord-
ingly, little consensus on the standard of care exists and participation in 
monthly costs: € 8,550 
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clinical trials is highly recommended [35]. For patients with BRAF-positive 
melanoma, targeted therapies focusing on the inhibition of BRAF or MEK 
have recently been approved [10]. 
In May and August 2013, respectively, the BRAF inhibitor dabrafenib was 
approved by the FDA and the EMA for the treatment of adult patients with 
unresectable or metastatic melanoma with BRAF V600 mutation. Both ap-
provals were mainly based on the interim results of one ongoing phase III 
trial [2, 4]. While the EMA has licensed dabrafenib for all types of V600 mu-
tation, the FDA has limited its approval to patients with V600E mutations 
only. This is due to a different assessment of the phase II-trial results by the 
authorities. The reviewers of the FDA pointed out that the antitumor activi-
ty in V600K patients was limited and V600K patients may represent a dis-
tinct subset of melanoma patients with distinct clinicopathologic features 
[36]. In contrast, the committee for medicinal products at the EMA conclud-
ed that, based on the same results, there was enough evidence for a broader 
indication of “V600 mutation”, although the inhibiting activity of dabraf-
enib seems to be lower in V600K patients [31]. Aside from this, there are no 
limitations in the European or US approval regarding the pretreatment of 
the patients, although the confirmatory trial had been restricted to previous-
ly untreated patients only. 
In this trial (BREAK-3) [22-24, 30], dabrafenib was investigated as first-line 
therapy in comparison to standard chemotherapy with DTIC. For patients 
in the chemotherapy group, crossing over to dabrafenib was allowed after in-
itial disease progression. After a median follow-up of about 10 months, sta-
tistically significant better PFS (6.9 months vs. 2.7 months) and ORR (59% 
vs. 24%) for dabrafenib were reported. At the time of a further interim anal-
ysis after 15 months follow-up, OS was comparable between the two groups 
(HR 0.76, 95% CI 0.48 - 1.21), but this HR is uncertain because the OS data 
were not mature and the results may be confounded by a cross-over rate of 
59% of all patients in the DTIC group.  
The majority of AEs was lower-grade and there were quite similar rates of 
serious AEs of about 25% in both groups. The most frequent AEs in the 
dabrafenib group were hyperkeratosis, rash, alopecia, and skin papillomas, 
while nausea, vomiting, fatigue, and neutropenia were more frequent in pa-
tients treated with DTIC. Beside this, it has to be mentioned that 10% of the 
patients treated with dabrafenib developed squamous cell carcinoma of the 
skin. This development of cutaneous squamous cell carcinoma may result 
from a shared risk factor with melanoma, the ultraviolet light exposure, and 
therefore the need for additional monitoring to survey patients with specific 
risk factors for this secondary cancer (e.g. smoking, alcohol, family history, 
etc.) may be indicated [37, 38]. To date, it is unknown whether a longer du-
ration of treatment or a combination of dabrafenib with other drugs lead to 
an even higher rate of patients developing secondary cancers. These ques-
tions may in part be answered by the currently ongoing phase III trials in-
vestigating the safety and efficacy of dabrafenib in combination with the 
MEK inhibitor trametinib. 
Although health-related QoL was defined as a secondary endpoint in the 
BREAK-3 trial, to date no meaningful results are available, since the num-
ber of assessments decreased throughout the trial and data were only report-
ed for the first 15 weeks [31]. 
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Despite improvement in PFS and a good response rate under treatment with 
BRAF inhibitors compared to standard chemotherapy, the majority of pa-
tients will develop disease progression following tumour regression within 6-
8 months [34, 39]. For this acquired resistance of melanoma to BRAF inhib-
itors, several mechanisms have been described in the literature, and due to 
further explorations of these mechanisms improved outcomes with BRAF 
inhibitor therapy might be possible. Therefore a number of studies are ei-
ther underway or planned to determine the best strategies in overcoming 
and/or delaying this intrinsic and acquired resistance [40]. 
In summary, on the one hand, results of the BREAK-3 trial indicate higher 
response rates and a longer PFS with dabrafenib compared to standard 
chemotherapy. But on the other hand, one has to consider a quite high tox-
icity and especially a rapid development of cutaneous squamous cell carci-
noma as a secondary cancer under treatment with dabrafenib. Furthermore, 
meaningful data on patients’ quality of life are not available yet and the ac-
tual costs for the treatment of melanoma patients with dabrafenib for Aus-
tria are not yet known. One also has to consider that expenses in future will 
be double or even higher if dabrafenib will be combined with other new 
agents like trametinib, a combination which for instance is currently under 
investigation. 
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